The Glasgow Prognostic Score (GPS) is an inflammation-based cumulative prognostic score calculated from C-reactive protein (CRP) and albumin levels. The aim of this study is to assess the value of GPS as a prognostic score in advanced gastric cancer patients undergoing gastro-jejunostomy. We retrospectively reviewed the medical records of 46 advanced gastric cancer patients treated with gastro-jejunostomy. Patients with both an elevated CRP (>1.0 mg/dL) and hypoalbuminemia (<3.5 mg/dL) were assigned a GPS of 2. Patients who presented with one of these biochemical abnormalities were assigned a GPS of 1, and patients with a normal CRP and albumin were assigned a score of 0. Multivariate analyses were performed to evaluate the factors that affected overall survival (OS). These analyses showed that peritoneal metastasis (P1or CY1) (HR : 11.142, 95%CI : 1.290-96.226, p=0.0284), GPS 2 (HR : 11.132, 95%CI : 3.041-40.752, p=0.0003) and treatment without chemotherapy (HR : 14.512, 95%CI : 3.611-58.327, p=0.0002) were independent prognostic factors for shorter OS. ECOG-PS was not a significant independent predictor of survival (HR : 0.617, 95%CI : 0.140-2.723, p=0.5236). Higher GPS grading was associated with shorter OS with median survival times in the groups with a GPS of 0, 1 and 2 were 341, 294 and 174 days respectively. The present study suggests that GPS predicts overall survival in advanced gastric cancer patients undergoing gastro-jejunostomy.